无创通气与经鼻高流量氧疗联合无呼吸氧合用于急性低氧性呼吸衰竭患者插管前预氧合的随机多中心开放标签试验
FLORALI-2多中心开放标签随机试验在法国28个ICU纳入313例急性低氧性呼吸衰竭(PaO2/FiO2≤300 mm Hg)需气管插管的成人患者,1:1随机接受无创通气或经鼻高流量氧疗预氧合(联合无呼吸氧合),按PaO2/FiO2(≤200 vs >200 mm Hg)分层。主要终点插管过程中严重低氧血症(脉搏血氧饱和度<80%)在无创通气组33/142(23%) vs 高流量组47/171(27%),绝对差异-4.2%(95%CI -13.7至5.5),P=0.39,无统计学显著差异。在242例中重度低氧血症(PaO2/FiO2≤200 mm Hg)患者中,无创通气组严重低氧血症28/117(24%) vs 高流量组44/125(35%),调整OR 0.56(95%CI 0.32至0.99),P=0.0459。严重不良事件两组无差异。
要点
- 急性低氧性呼吸衰竭(PaO2/FiO2≤300 mm Hg)插管前预氧合,无创通气组严重低氧血症(SpO2<80%)23%(33/142) vs 高流量组27%(47/171),绝对差异-4.2%(95%CI -13.7至5.5),P=0.39,无统计学显著差异。
- 基线PaO2/FiO2≤200 mm Hg的242例中重度低氧血症患者,无创通气组严重低氧血症24%(28/117) vs 高流量组35%(44/125),调整OR 0.56(95%CI 0.32至0.99),P=0.0459。
- 两组严重不良事件无差异;常见即刻并发症为收缩压降低(无创通气组49% vs 高流量组50%)和胸部X线浸润影(20% vs 19%)。
- 常见晚期并发症为第28天死亡(无创通气组37% vs 高流量组34%)和ICU期间呼吸机相关性肺炎(22% vs 20%)。
- 作者认为未来研究应探索基线中重度低氧血症患者中预氧合方法的效果。
适用人群与场景
- 成人急性低氧性呼吸衰竭需气管插管患者,PaO2/FiO2≤300 mm Hg,在ICU接受预氧合。
- 排除:心脏骤停插管、意识改变(Glasgow昏迷评分<8分)、无创通气其他禁忌证(近期喉、食管或胃手术,以及严重面部骨折)、无法获得脉搏血氧饱和度、孕妇或哺乳期妇女、拒绝参与。
诊断标准与关键阈值
- 急性低氧性呼吸衰竭定义:PaO2/FiO2≤300 mm Hg。
- 按PaO2/FiO2分层:≤200 mm Hg vs >200 mm Hg。
- 主要终点严重低氧血症定义:插管过程中脉搏血氧饱和度<80%。
研究设计与关键结果
- 研究类型:多中心、开放标签、随机对照试验(FLORALI-2),法国28个ICU,2016年4月15日至2017年1月8日。
- 样本量:2079例插管患者中322例入组,313例纳入意向性治疗分析(无创通气组142例,高流量组171例)。
- 干预与对照:预氧合期间无创通气 vs 经鼻高流量氧疗(均联合无呼吸氧合)。
- 主要终点:严重低氧血症(SpO2<80%)无创通气组33/142(23%) vs 高流量组47/171(27%),绝对差异-4.2%(95%CI -13.7至5.5),P=0.39,无统计学显著差异。
- 亚组:PaO2/FiO2≤200 mm Hg的242例中,严重低氧血症无创通气组28/117(24%) vs 高流量组44/125(35%),调整OR 0.56(95%CI 0.32至0.99),P=0.0459。
- 严重不良事件两组无差异;即刻并发症:收缩压降低无创通气组70/142(49%) vs 高流量组86/171(50%),胸部X线浸润影28/142(20%) vs 33/171(19%);晚期并发症:第28天死亡53/142(37%) vs 58/171(34%),ICU期间呼吸机相关性肺炎31/142(22%) vs 35/171(20%)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急性低氧性呼吸衰竭(PaO2/FiO2≤300 mm Hg)患者插管前预氧合时,无创通气或经鼻高流量氧疗均未改变严重低氧血症风险。
- 作者认为未来研究应探索基线中重度低氧血症(PaO2/FiO2≤200 mm Hg)患者中预氧合方法的效果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Non-invasive ventilation has never been compared with high-flow oxygen to determine whether it reduces the risk of severe hypoxaemia during intubation. We aimed to determine if preoxygenation with non-invasive ventilation was more efficient than high-flow oxygen in reducing the risk of severe hypoxaemia during intubation.
METHODS: The FLORALI-2 multicentre, open-label trial was done in 28 intensive care units in France. Adult patients undergoing tracheal intubation for acute hypoxaemic respiratory failure (a partial pressure of arterial oxygen [PaO2] to fraction of inspired oxygen [FiO2] ratio of ≤300 mm Hg) were randomly assigned (1:1; block size, four participants) to non-invasive ventilation or high-flow oxygen during preoxygenation, with stratification by PaO2/FiO2 ratio (≤200 mm Hg vs >200 mm Hg). Key exclusion criteria were intubation for cardiac arrest, altered consciousness (defined as a Glasgow coma score of less than eight points), other contraindications to non-invasive ventilation (recent laryngeal, oesophageal, or gastric surgery, and substantial facial fractures), pulse oximetry not available, pregnant or breastfeeding women, and refusal to participate. The primary outcome was the occurrence of severe hypoxaemia (pulse oximetry <80%) during the procedure, assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02668458.
FINDINGS: Between April 15, 2016, and Jan 8, 2017, 2079 patients were intubated in the 28 participating units, and 322 were enrolled. We excluded five patients with no recorded data, two who withdrew consent or were under legal protection, one who was not intubated, and one who had a cardiac arrest. Of the 313 patients included in the intention-to-treat analysis, 142 were assigned to non-invasive ventilation and 171 to high-flow oxygen therapy. Severe hypoxaemia occurred in 33 (23%) of 142 patients after preoxygenation with non-invasive ventilation and 47 (27%) of 171 with high-flow oxygen (absolute difference -4·2%, 95% CI -13·7 to 5·5; p=0·39). In the 242 patients with moderate-to-severe hypoxaemia (PaO2/FiO2 ≤200 mm Hg), severe hypoxaemia occurred less frequently after preoxygenation with non-invasive ventilation than with high-flow oxygen (28 [24%] of 117 patients vs 44 [35%] of 125; adjusted odds ratio 0·56, 0·32 to 0·99, p=0·0459). Serious adverse events did not differ between treatment groups, with the most common immediate complications being systolic arterial hypotension (70 [49%] patients in the non-invasive ventilation group vs 86 [50%] patients in the high-flow oxygen group) and chest infiltrate on x-ray (28 [20%] vs 33 [19%]), and the most common late complications being death at day 28 (53 [37%] vs 58 [34%]) and ventilator-associated pneumonia during ICU stay (31 [22%] vs 35 [20%]).
INTERPRETATION: In patients with acute hypoxaemic respiratory failure, preoxygenation with non-invasive ventilation or high-flow oxygen therapy did not change the risk of severe hypoxaemia. Future research should explore the effect of preoxygenation method in patients with moderate-to-severe hypoxaemia at baseline.
FUNDING: French Ministry of Health.
参考来源
- Frat JP, Ricard JD, Quenot JP, et al. Non-invasive ventilation versus high-flow nasal cannula oxygen therapy with apnoeic oxygenation for preoxygenation before intubation of patients with acute hypoxaemic respiratory failure: a randomised, multicentre, open-label trial. Lancet Respir Med. 2019. PMID: 30898520. doi:10.1016/S2213-2600(19)30048-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。